X

Drug Profile

Research programme: cancer antibody therapies - Celera/Seagen

Latest Information Update: 18 Dec 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Celera Genomics Group; Seattle Genetics
Developer Celera Corporation; Seattle Genetics
Class Monoclonal antibodies
Mechanism of Action

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Discontinued Cancer

Most Recent Events

08 Oct 2020 Seattle Genetics is now called Seagen
20 Jun 2005 This programme is still in active development
29 Jul 2004 Celera Genomics and Seattle Genetics have entered into an agreement to co-develop targeted antibody therapies in USA for cancer

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com